DOCSLIB.ORG

Morphine Priming in Rats with Chronic Inflammation Reveals a Dichotomy Between Antihyperalgesic and Antinociceptive Properties of Deltorphin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Morphine Priming in Rats with Chronic Inflammation Reveals a Dichotomy Between Antihyperalgesic and Antinociceptive Properties of Deltorphin Neuroscience 144 (2007) 263–274 MORPHINE PRIMING IN RATS WITH CHRONIC INFLAMMATION REVEALS A DICHOTOMY BETWEEN ANTIHYPERALGESIC AND ANTINOCICEPTIVE PROPERTIES OF DELTORPHIN L. GENDRON,a1 M. J. ESDAILE,a F. MENNICKEN,b strongly reduced the antinociceptive efficacy of the drug H. PAN,d D. O’DONNELL,b J.-P. VINCENT,e L. A. DEVI,d (tail-flick test; % maximum possible antinociceptive effect versus 66.6%؎6.3% in rats injected with %3.6؎%29.6؍(C. M. CAHILL,c T. STROHa AND A. BEAUDETa* (MPE a CFA alone) suggesting that the latter, but not the former, is Department of Neurology and Neurosurgery, Montreal Neurological ␦ Institute, Room 896, 3801 University Street, McGill University, Mon- linked to the OR trafficking events observed neuroanatomi- treal, Quebec, Canada H3A 2B4 cally. These results demonstrate that in chronic inflamma- tion, the antihyperalgesic effects of ␦OR agonists may be b AstraZeneca R&D Montreal, Ville St.-Laurent, Quebec, Canada H4S enhanced by morphine pre-treatment. They also reveal a di- 1Z9 chotomy between mechanisms underlying antihyperalgesic cDepartment of Pharmacology and Toxicology, Botterell Hall, Queen’s and antinociceptive effects of ␦OR agonists. © 2006 IBRO. University, Kingston, Ontario, Canada K7L 3N6 Published by Elsevier Ltd. All rights reserved. dDepartment of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, NY 10029, USA Key words: delta opioid receptor, deltorphin, chronic inflam- mation, antihyperalgesia, antinociception, tolerance. eInstitut de Pharmacologie Moléculaire et Cellulaire, Unité Mixte de Recherche 6097 du CNRS, 06560 Valbonne, France Agonists acting through the mu opioid receptor (␮OR), Abstract—We previously showed that prolonged morphine such as morphine and its derivatives, induce potent anal- treatment and chronic inflammation both enhanced delta gesic effects (Bodnar and Klein, 2004). However, they also opioid receptor (␦OR) cell surface density in lumbar spinal give rise to undesirable side-effects such as nausea, con- cord neurons. Here, we sought to determine whether ad- stipation, and respiratory depression (Colpaert, 1996; ministration of morphine to rats with chronic inflammation Kreek, 1996). In addition, chronic stimulation of ␮OR in- would further increase the bio-availability of ␦OR, and ␦ duces tolerance and physical dependence (Cowan et al., thereby the analgesic properties of the OR agonist deltor- ␦ phin, over that produced by inflammation alone. We found 1988). By contrast, drugs acting on OR produce more that chronic inflammation produced by injection of com- limited analgesia, but also give rise to considerably less plete Freund’s adjuvant (CFA) into the hind paw resulted in undesirable side-effects and induce virtually no tolerance a bilateral increase in the binding and internalization of (Porreca et al., 1984; May et al., 1989; Sheldon et al., fluorescent deltorphin in neurons of the lumbar spinal cord 1990; Szeto et al., 1999; Gallantine and Meert, 2005). For as did prolonged morphine treatment [Morinville A, Cahill these reasons, ␦OR agonists have been proposed as pos- CM, Aibak H, Rymar VV, Pradhan A, Hoffert C, Mennicken F, sible alternatives to ␮OR agonists for the treatment of Stroh T, Sadikot AF, O’Donnell D, Clarke PB, Collier B, Henry JL, Vincent JP, Beaudet A (2004a) Morphine-induced chronic pain, including neuropathic (Mika et al., 2001; Petrillo changes in delta opioid receptor trafficking are linked to et al., 2003; Morinville et al., 2004a) and chronic inflammatory somatosensory processing in the rat spinal cord. J Neuro- pain (Desmeules et al., 1993; Stewart and Hammond, 1994; sci 24:5549–5559]. This effect was accompanied by an Fraser et al., 2000; Hurley and Hammond, 2000; Qiu et al., increase in the antinociceptive efficacy of intrathecal del- 2000; Cahill et al., 2003; Petrillo et al., 2003). torphin as measured using the tail-flick test. Treatment of One of the reasons for the relatively poor analgesic CFA-injected rats with morphine decreased the cell surface ␦ ␦ efficiency of OR agonists may be that only a small pro- availability of OR in neurons of the dorsal horn of the ␦ lumbar spinal cord as compared with treatment with CFA portion of OR is actually present on neuronal plasma alone. Behaviorally, it significantly enhanced the antihy- membranes under baseline conditions (Cheng et al., 1995, peralgesic effects of deltorphin (plantar test; % maximum 1997; Elde et al., 1995; Zhang et al., 1998; Cahill et al., -2001a). However, under conditions of chronic inflamma %32.4؎%113.5؍(possible antihyperalgesic effect (MPAHE versus 26.1%؎11.6% in rats injected with CFA alone) but tion, such as produced in rodents by injection of complete 1 Present address: Department of Physiology and Biophysics, Faculty Freund’s adjuvant (CFA) in the hind paw, we observed a of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada, massive recruitment of ␦OR from intracellular stores to the J1H 5N4. plasma membrane in neurons of the dorsal horn of the ϩ ϩ *Corresponding author. Tel: 1-514-398-1913; fax: 1-514-398-5871. spinal cord (Cahill et al., 2003; Morinville et al., 2004b). E-mail address: [email protected] (A. Beaudet). Abbreviations: CFA, complete Freund’s adjuvant; DRG, dorsal root This increase in the pharmacological availability of ␦OR ganglion; Fluo-DLT, ␻-Bodipy 576/589 deltorphin-I 5-aminopentylam- was postulated to account for the enhanced antihyperal- ide; i.t., intrathecal/intrathecally; MPAHE, maximum possible antihy- gesic efficacy of the centrally administered ␦OR agonists peralgesic effect; MPE, maximum possible antinociceptive effect; MS, morphine sulfate; ␮OR, mu opioid receptor; PB, phosphate buffer; reported in conditions of chronic inflammation (Hylden RIA, radioimmunoassay. et al., 1991; Stewart and Hammond, 1994; Fraser et al., 0306-4522/07$30.00ϩ0.00 © 2006 IBRO. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.neuroscience.2006.08.077 263 264 L. Gendron et al. / Neuroscience 144 (2007) 263–274 2000; Hurley and Hammond, 2000; Cahill et al., 2003; were carried out 12 h after the last morphine or saline injection. To Morinville et al., 2004b). The CFA-induced up-regulation of determine the dose-response of morphine pre-treatment on the cell surface ␦OR in spinal cord neurons involves the par- antinociceptive efficacy of deltorphin, additional groups of naïve rats were treated: (1) for 48 h with half (1, 3, 5, and 8 mg/kg; low ticipation of ␮OR as it can no longer be elicited in ␮OR dose) or twice (10, 15, 20 and 30 mg/kg; high dose) the standard knockout mice (Morinville et al., 2004b). The effect of morphine dose; or (2) for 96 h with a modified standard morphine chronic inflammation on ␦OR trafficking is therefore akin to dose (5, 8, 10, 10, 10, 10, 10, 15 mg/kg). that of prolonged treatment with ␮OR-preferring agonists (including morphine, fentanyl, methadone and etorphine), In vivo ␦OR internalization assay which was shown to induce a selective membrane recruit- ␦ ␦ To assess the cell surface availability of OR in neurons of the ment of OR in neurons of layers I–VI of the rat lumbar lumbar spinal cord (L4-5), naïve rats (nϭ3), rats treated with CFA spinal cord (Cahill et al., 2001b; Morinville et al., 2003). As 72 h earlier (nϭ3), and rats treated with CFA and subjected to in animals with chronic inflammation, this increased den- prolonged treatment with morphine (standard dose; nϭ3) were sity of cell surface ␦OR translates into a potentiation of the injected i.t. with 30 ␮lof␻-Bodipy 576/589 deltorphin-I 5-amin- antinociceptive properties of deltorphin II injected intrathe- opentylamide (Fluo-DLT) as described (Morinville et al., 2004a). cally (i.t.) (Cahill et al., 2001b; Morinville et al., 2003). Briefly, animals were anesthetized with sodium pentobarbital (Somnotol; MTC Pharmaceuticals, Cambridge, Ontario, Canada, However, it is unclear whether chronic inflammation and 6.5 mg/100 g of body weight) and injected i.t. via a lumbar punc- sustained morphine treatment affect the same neuronal ture with 0.8 nmol Fluo-DLT diluted in 30 ␮l saline at the L5–L6 populations in the lumbar spinal cord and whether their intervertebral space. Appropriate placement of the needle was effects are independent or cumulative. validated by the observation of a little flick of the tail. Twenty The aim of the present study was therefore to investi- minutes after injection of the fluorescent ligand, rats were killed by gate the distribution of neurons which up-regulate cell intra-aortic arch perfusion of, in succession, 4% paraformalde- hyde (PFA) in 500 ml 0.1 M phosphate buffer (PB, pH 7.4) at 4 °C surface ␦OR in the lumbar spinal cord in response to and 100 ml each of 10%, 20%, and 30% sucrose in 0.2 M PB (pH chronic inflammation of the hind paw and to determine 7.4). The lumbar segment of the spinal cord was snap-frozen in whether this up-regulation is affected by a morphine treat- isopentane at Ϫ45 °C and stored at Ϫ80 °C until sectioning. ment in an attempt to determine if pre-treatment of animals Tissues were sectioned on a cryostat at a thickness of 20 ␮m and with morphine (to heighten the cell surface density of ␦OR) thaw-mounted onto chrome alum/gelatin-coated slides (without would further enhance the analgesic efficacy of ␦OR ago- coverslips). nists in the treatment of chronic pain. Neurons having specifically bound and internalized Fluo-DLT (characterized by the presence of intra-cytoplasmic fluorescent puncta) were visualized using a Zeiss confocal laser scanning EXPERIMENTAL PROCEDURES microscope LSM510 (Carl Zeiss Canada Ltd., Toronto, Ontario, Canada) equipped with an inverted microscope (oil-immersion Animals objectives, 25ϫ,40ϫ and 63ϫ) and a He/Ne laser with an exci- tation wavelength of 543 nm. For each animal, five representative All experiments were carried out in adult male Sprague–Dawley images were acquired on each side of the lumbar spinal cord, rats (220–280 g; Charles River, St-Constant, Quebec, Canada), contralateral and ipsilateral to the inflamed paw, in each of lami- maintained on a 12-h light/dark cycle.
Load more

Recommended publications
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Opioid Tolerance in Methadone Maintenance Treatment: Comparison
    Gutwinski et al. Harm Reduction Journal (2016) 13:7 DOI 10.1186/s12954-016-0095-0 RESEARCH Open Access Opioid tolerance in methadone maintenance treatment: comparison of methadone and levomethadone in long-term treatment Stefan Gutwinski*, Nikola Schoofs, Heiner Stuke, Thomas G. Riemer, Corinde E. Wiers and Felix Bermpohl Abstract Background: This study aimed to investigate the development of opioid tolerance in patients receiving long-term methadone maintenance treatment (MMT). Methods: A region-wide cross-sectional study was performed focusing on dosage and duration of treatment. Differences between racemic methadone and levomethadone were examined. All 20 psychiatric hospitals and all 110 outpatient clinics in Berlin licensed to offer MMT were approached in order to reach patients under MMT fulfilling the DSM IV criteria of opiate dependence. In the study, 720 patients treated with racemic methadone or levomethadone gave information on the dosage of treatment. Out of these, 679 patients indicated the duration of MMT. Results: Treatment with racemic methadone was reported for 370 patients (54.5 %), with levomethadone for 309 patients (45.5 %). Mean duration of MMT was 7.5 years. We found a significant correlation between dosage and duration of treatment, both in a conjoint analysis for the two substances racemic methadone and levomethadone and for each substance separately. These effects remained significant when only patients receiving MMT for 1 year or longer were considered, indicating proceeding tolerance development in long-term treatment. When correlations were compared between racemic methadone and levomethadone, no significant difference was found. Conclusions: Our data show a tolerance development under long-term treatment with both racemic methadone and levomethadone.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Nitrous Oxide in Emergency Medicine Í O’ Sullivan, J Benger
    214 ANALGESIA Emerg Med J: first published as 10.1136/emj.20.3.214 on 1 May 2003. Downloaded from Nitrous oxide in emergency medicine Í O’ Sullivan, J Benger ............................................................................................................................. Emerg Med J 2003;20:214–217 Safe and predictable analgesia is required for the identify these zones as there is considerable vari- potentially painful or uncomfortable procedures often ation between people. He also emphasised the importance of the patient’s pre-existing beliefs. If undertaken in an emergency department. The volunteers expect to fall asleep while inhaling characteristics of an ideal analgesic agent are safety, 30% N2O then a high proportion do so. An appro- predictability, non-invasive delivery, freedom from side priate physical and psychological environment increases the actions of N2O and may allow lower effects, simplicity of use, and a rapid onset and offset. doses to be more effective. Unlike many other Newer approaches have threatened the widespread use anaesthetic agents, N2O exhibits an acute toler- of nitrous oxide, but despite its long history this simple ance effect, whereby its potency is greater at induction than after a period of “accommoda- gas still has much to offer. tion”. .......................................................................... MECHANISM OF ACTION “I am sure the air in heaven must be this Some writers have suggested that N2O, like wonder-working gas of delight”. volatile anaesthetics, causes non-specific central nervous system depression. Others, such as 4 Robert Southey, Poet (1774 to 1843) Gillman, propose that N2O acts specifically by interacting with the endogenous opioid system. HISTORY N2O is known to act preferentially on areas of the Nitrous oxide (N2O) is the oldest known anaes- brain and spinal cord that are rich in morphine thetic agent.
    [Show full text]
  • Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides
    bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title page Title: Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides Short title: Rubsicolins are G-protein-biased peptides Authors: Robert J. Cassell1†, Kendall L. Mores1†, Breanna L. Zerfas1, Amr H.Mahmoud1, Markus A. Lill1,2,3, Darci J. Trader1,2,3, Richard M. van Rijn1,2,3 Author affiliation: 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, 2Purdue Institute for Drug Discovery, 3Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907 †Robert J Cassell and Kendall Mores contributed equally to this work Corresponding author: ‡Richard M. van Rijn, Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907 (Phone: 765-494- 6461; Email: [email protected]) Key words: delta opioid receptor; beta-arrestin; natural products; biased signaling; rubisco; G protein-coupled receptor Abstract: 187 Figures: 2 Tables: 2 References: 27 1 bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The impact that β-arrestin proteins have on G-protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin.
    [Show full text]
  • Intravta Deltorphin, but Not DPDPE, Induces Place Preference in Ethanoldrinking Rats
    ALCOHOLISM:CLINICAL AND EXPERIMENTAL RESEARCH Vol. 38, No. 1 January 2014 Intra-VTA Deltorphin, But Not DPDPE, Induces Place Preference in Ethanol-Drinking Rats: Distinct DOR-1 and DOR-2 Mechanisms Control Ethanol Consumption and Reward Jennifer M. Mitchell, Elyssa B. Margolis, Allison R. Coker, Daicia C. Allen, and Howard L. Fields Background: While there is a growing body of evidence that the delta opioid receptor (DOR) modu- lates ethanol (EtOH) consumption, development of DOR-based medications is limited in part because there are 2 pharmacologically distinct DOR subtypes (DOR-1 and DOR-2) that can have opposing actions on behavior. Methods: We studied the behavioral influence of the DOR-1-selective agonist [D-Pen2,D-Pen5]- Enkephalin (DPDPE) and the DOR-2-selective agonist deltorphin microinjected into the ventral tegmental area (VTA) on EtOH consumption and conditioned place preference (CPP) and the physio- logical effects of these 2 DOR agonists on GABAergic synaptic transmission in VTA-containing brain slices from Lewis rats. Results: Neither deltorphin nor DPDPE induced a significant place preference in EtOH-na€ıve Lewis rats. However, deltorphin (but not DPDPE) induced a significant CPP in EtOH-drinking rats. In con- trast to the previous finding that intra-VTA DOR-1 activity inhibits EtOH consumption and that this inhibition correlates with a DPDPE-induced inhibition of GABA release, here we found no effect of DOR-2 activity on EtOH consumption nor was there a correlation between level of drinking and deltorphin-induced change in GABAergic synaptic transmission. Conclusions: These data indicate that the therapeutic potential of DOR agonists for alcohol abuse is through a selective action at the DOR-1 form of the receptor.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • What Are the Treatments for Heroin Addiction?
    How is heroin linked to prescription drug abuse? See page 3. from the director: Research Report Series Heroin is a highly addictive opioid drug, and its use has repercussions that extend far beyond the individual user. The medical and social consequences of drug use—such as hepatitis, HIV/AIDS, fetal effects, crime, violence, and disruptions in family, workplace, and educational environments—have a devastating impact on society and cost billions of dollars each year. Although heroin use in the general population is rather low, the numbers of people starting to use heroin have been steadily rising since 2007.1 This may be due in part to a shift from abuse of prescription pain relievers to heroin as a readily available, cheaper alternative2-5 and the misperception that highly pure heroin is safer than less pure forms because it does not need to be injected. Like many other chronic diseases, addiction can be treated. Medications HEROIN are available to treat heroin addiction while reducing drug cravings and withdrawal symptoms, improving the odds of achieving abstinence. There are now a variety of medications that can be tailored to a person’s recovery needs while taking into account co-occurring What is heroin and health conditions. Medication combined with behavioral therapy is particularly how is it used? effective, offering hope to individuals who suffer from addiction and for those around them. eroin is an illegal, highly addictive drug processed from morphine, a naturally occurring substance extracted from the seed pod of certain varieties The National Institute on Drug Abuse (NIDA) has developed this publication to Hof poppy plants.
    [Show full text]
  • Receptor Types
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 3180-3184, April 1990 Pharmacology Chimeric opioid peptides: Tools for identifying opioid receptor types (dynorphin/dermorphin/deltorphin/monoclonal antibody/panning) Guo-xi XIE*t, ATSUSHI MIYAJIMA*, TAKASHI YOKOTA*, KEN-ICHI ARAI*, AND AVRAM GOLDSTEINt *Department of Molecular Biology, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304; and tDepartment of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, January 23, 1990 ABSTRACT We synthesized several chimeric peptides in was assumed that the C-terminal amide group ofdermorphin, which the N-terminal nine residues of dynorphin-32, a peptide deltorphins, and DSLET and the alcohol group of DAGO selective for the K opioid receptor, were replaced by opioid could be removed without affecting opioid binding. By anal- peptides selective for other opioid receptor types. Each chi- ogy to dyn-32, which binds selectively to K opioid sites, meric peptide retained the high affminty and type selectivity DAGO-DYN and dermorphin-DYN should bind selectively characteristic of its N-terminal sequence. The common C- to p.; deltorphins-DYN and DSLET-DYN should bind selec- terminal two-thirds of the chimeric peptides served as an tively to 8. mAbs 17.M and 39 should act as nonblocking epitope recognized by the same monoclonal antibody. When antibodies to all these peptides. bound to receptors on a cell surface or membrane preparation, In the present study, we have demonstrated that the these peptides could still bind specifically to the monoclonal chimeric peptides do maintain the high affinities and type antibody. These chimeric peptides should be useful for isolating selectivities of their N-terminal sequences.
    [Show full text]
  • The Effects of the Morphine Analogue Levorphanol on Leukocytes: Metabolic Effects at Rest and During Phagocytosis
    The effects of the morphine analogue levorphanol on leukocytes: Metabolic effects at rest and during phagocytosis Nancy Wurster, … , Penelope Pettis, Sharon Lebow J Clin Invest. 1971;50(5):1091-1099. https://doi.org/10.1172/JCI106580. Studies on bacteria have suggested that morphine-like drugs have effects on the cell membrane. To determine the effect of this class of drugs on a mammalian cell, we selected the rabbit peritoneal exudate granulocyte, which undergoes striking membrane changes during phagocytosis. We examined the effect in vitro of the morphine analogue, levorphanol on phagocytosis and metabolism by granulocytes incubated with and without polystyrene particles or live Escherichia coli. Levorphanol (1 or 2 mmoles/liter) decreased: (a) acylation of lysolecithin or lysophosphatidylethanolamine in the medium (which is stimulated about two-fold during phagocytosis) both at rest (40%) and during phagocytosis (60%); (b) uptake of latex particles and Escherichia coli, as judged by electron microscopy; (c) killing of live Escherichia coli (10-fold); (d) 14 14 + CO2 production from glucose-1- C during phagocytosis by at least 80%; (e) K content of granulocytes (35%); (f) oxidation of linoleate-1-14C by 50%, and its incorporation into triglyceride by more than 80%. However, levorphanol stimulated 2 to 3-fold the incorporation of linoleate-1-14C or palmitate-1-14C into several phospholipids. Glucose uptake, lactate production, and adenosine triphosphate (ATP) content are not affected by the drug. Thus, levorphanol does not appear to exert its effects through generalized metabolic suppression. Removal of levorphanol by twice resuspending the granulocytes completely reverses all inhibition. In line with observations on bacteria, it appears that the complex effects of levorphanol on […] Find the latest version: https://jci.me/106580/pdf The Effects of the Morphine Analogue Levorphanol on Leukocytes METABOLIC EFFECTS AT REST AND DURING PHAGOCYTOSIS NANcY WuRsTE, PETER ELSBACH, ERIc J.
    [Show full text]
  • Opioid Receptors in Immune and Glial Cells—Implications for Pain Control
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Repository of the Freie Universität Berlin REVIEW published: 04 March 2020 doi: 10.3389/fimmu.2020.00300 Opioid Receptors in Immune and Glial Cells—Implications for Pain Control Halina Machelska* and Melih Ö. Celik Department of Experimental Anesthesiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany Opioid receptors comprise µ (MOP), δ (DOP), κ (KOP), and nociceptin/orphanin FQ (NOP) receptors. Opioids are agonists of MOP, DOP, and KOP receptors, whereas nociceptin/orphanin FQ (N/OFQ) is an agonist of NOP receptors. Activation of all four opioid receptors in neurons can induce analgesia in animal models, but the most clinically relevant are MOP receptor agonists (e.g., morphine, fentanyl). Opioids can also affect the function of immune cells, and their actions in relation to immunosuppression and infections have been widely discussed. Here, we analyze the expression and the role of opioid receptors in peripheral immune cells and glia in the modulation of pain. All four opioid receptors have been identified at the mRNA and protein levels in Edited by: immune cells (lymphocytes, granulocytes, monocytes, macrophages) in humans, rhesus Sabita Roy, monkeys, rats or mice. Activation of leukocyte MOP, DOP, and KOP receptors was University of Miami, United States recently reported to attenuate pain after nerve injury in mice. This involved intracellular Reviewed by: 2+ Lawrence Toll, Ca -regulated release of opioid peptides from immune cells, which subsequently Florida Atlantic University, activated MOP, DOP, and KOP receptors on peripheral neurons.
    [Show full text]